返回 
加入收藏
参松养心胶囊联合依达拉奉治疗脑血管疾病并发脑心综合征的临床观察
x
请在关注微信后，向客服人员索取文件
| 篇名： | 参松养心胶囊联合依达拉奉治疗脑血管疾病并发脑心综合征的临床观察 |
| TITLE： | |
| 摘要： | 目的：观察参松养心胶囊联合依达拉奉治疗脑血管疾病并发脑心综合征（CCS）的疗效和安全性。方法：128例脑血管疾病并发CCS患者随机分为对照组（64例）和观察组（64例）。对照组患者给予常规治疗，观察组患者在对照组治疗的基础上给予参松养心胶囊1.6 g，每日3次，口服+依达拉奉注射液30 mg，加入0.9％氯化钠溶液250 mL中，静脉滴注，每日2次。两组疗程均为10 d。观察两组患者的临床疗效，治疗前后血清丙二醛（MDA）、超氧化物歧化酶（SOD）、儿茶酚胺[去甲肾上腺素（NE）、肾上腺素（E）、多巴胺（DA）] 水平、肌钙蛋白I（cTnI）、美国国立卫生研究院卒中量表评分（NIHSS），分析cTnI水平与NIHSS评分相关性，并记录不良反应发生情况。结果：观察组患者神经系统、心电图总有效率均显著高于对照组，差异均有统计学意义（P＜0.05）。治疗前，两组患者血清MDA、SOD、NE、E、DA、cTnI水平、NIHSS 评分比较，差异均无统计学意义（P＞0.05）。治疗后，两组患者血清MDA、NE、E、DA、cTnI水平、NIHSS 评分均显著低于同组治疗前，且观察组显著低于对照组；两组患者血清SOD水平均显著高于同组治疗前，且观察组显著高于对照组，差异均有统计学意义（P＜0.05）。cTnI水平与NIHSS 评分呈正相关（r＝0.956，P＝0.001）。两组患者不良反应发生率比较，差异无统计学意义（P＞0.05）。结论：在常规治疗的基础上，参松养心胶囊联合依达拉奉可显著提高脑血管疾病并发CCS患者的疗效，改善儿茶酚胺、MDA、SOD水平，且未增加不良反应的发生。 |
| ABSTRACT： | OBJECTIVE： To observe therapeutic efficacy and safety of Shensong yangxin capsules combined with edaravone in the treatment of cerebrovascular disease complicated with cerebrocardiac syndrome （CCS）. METHODS： A total of 128 cerebrovascular disease patients with CCS were randomly divided into control group （64 cases） and observation group （64 cases）. Control group received routine treatment， observation group was additionally given Shensong yangxin capsule 1.6 g orally， 3 times a day+Edaravone injection 30 mg added into 0.9％ Sodium chloride solution 250 mL intravenously， 2 times a day. Treatment courses of 2 groups lasted for 10 d. Clinical efficacies of 2 groups were observed， and MDA， SOD， catecholamine （NE， E， DA） levels， cTnI， NIHSS scores， correlation of cTnI level with NIHSS score were also observed before and after treatment. The occurrence of ADR was recorded. RESULTS： Total response rate of nervous system and electrocardio gram in observation group were significantly higher than control group， with statistical significance （P＜0.05）. Before treatment， there was no statistical significance in MDA， SOD， NE， E， DA， cTnI levels or NIHSS scores between 2 groups （P＞0.05）. After treatment， MDA， NE， E， DA， cTnI levels and NIHSS scores of 2 groups were significantly lower than before， and the observation group was significantly lower than the control group； SOD of 2 groups were significantly higher than before，and the observation group was significantly higher than the antrol group，with statistical significance （P＜0.05）. cTnI level was positively correlated with NIHSS score （r＝0.956，P＝0.001）. There was no statistical significance in the incidence of ADR between 2 groups （P＞0.05）. CONCLUSIONS： Based on routine treatment， Shensong yangxin capsules combined with edaravone can significantly improve therapeutic efficacy of cerebrovascular disease patients with CCS， and improve the levels of catecholamine， MDA and SOD without increasing the occurrence of ADR. |
| 期刊： | 2017年第28卷第33期 |
| 作者： | 李敬，张俊岭，姜瑞博，李颖，郑群，闫小菊 |
| AUTHORS： | LI Jing，ZHANG Junling，JIANG Ruibo，LI Ying，ZHENG Qun，YAN Xiaoju |
| 关键字： | 脑心综合征； 参松养心胶囊；依达拉奉；疗效；安全性 |
| KEYWORDS： | Cerebrovascular disease complicated with cerebral cardiac syndrome； Shensong yangxin capsule； Edaravone； Therapeutic efficacy； Safety |
| 阅读数： | 367 次 |
| 本月下载数： | 2 次 |
* 注：未经本站明确许可，任何网站不得非法盗链资源下载连接及抄袭本站原创内容资源!在此感谢您的支持与合作！
